A small biopharma company said its experimental depression drug is moving into Phase 3 trials, sending its shares soaring about 35% in premarket trading on Monday.
Pharmalittle: We’re reading about rising GLP-1 use, a psychedelic therapy for depression, and more
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback